<DOC>
	<DOCNO>NCT02711345</DOCNO>
	<brief_summary>A phase I study LTT462 patient advance solid tumor harbor MAPK pathway alteration .</brief_summary>
	<brief_title>A Phase I Clinical Study With Investigational Compound LTT462 Adult Patients With Specific Advanced Cancers</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<criteria>Patient ( male female ) ≥18 year age ECOG ( Eastern Cooperative Oncology Group ) performance status ≤1 Must progress follow standard therapy , , opinion Investigator , effective standard therapy exist , tolerated appropriate . Patients must willing able undergo study require biopsy . Presence least one measurable lesion accord RECIST v1.1 . Documented MAPK pathway alteration Prior treatment ERK inhibitor . History current evidence retinal vein occlusion ( RVO ) current risk factor RVO . Any medical condition would , investigator 's judgment , prevent patient 's participation clinical study due safety concern compliance clinical study procedure . Patients receive proton pump inhibitor ( PPI ) discontinue 3 day prior start study treatment duration study . Patients malignant disease treat study . Clinically significant cardiac disease . Other protocoldefined exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>LTT462</keyword>
	<keyword>ERK</keyword>
	<keyword>MAPK</keyword>
	<keyword>solid tumor</keyword>
</DOC>